Biofrontera Inc. (BFRI)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$6.5M
Cash & Equivalents
$0.1M
Quarterly Burn Rate
279 mo
Est. Cash Runway
$11M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (2 Assets)

DrugPhaseIndications
AMINOLEVULINIC ACID HYDROCHLORIDE
AMELUZ 		APPROVED —
BENZOYL PEROXIDE, ERYTHROMYCIN
AKTIPAK 		NDA —

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05662202 Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Acti... PHASE3 Active Not Recruiting 172

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BFRI.

SEC EDGAR Filings

All SEC filings for Biofrontera Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.